申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP0620225A1
公开(公告)日:1994-10-19
Cephalosporin derivatives of the general formula
wherein
R¹is an acyl group derived from a carboxylic acid;
R²is hydrogen, hydroxy, lower alkyl-Qm, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl-Qm, aryl-Qm, aryloxy, aralkoxy or a heterocyclic ring, the lower alkyl, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl, aryl, aryloxy, aralkoxy and the heterocyclic ring being unsubstituted or substituted with at least one group selected from carboxy, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, -CONR⁴R⁵, -N(R⁵)COOR⁹, R⁵CO-, R⁵OCO- or R⁵COO- where R⁴ is hydrogen, lower alkyl, or cycloalkyl; R⁵ is hydrogen or lower alkyl; R⁹ is hydrogen, lower alkyl, lower alkenyl or a carboxylic acid protecting group;
Qis -CO- or -SO₂-;
mis 0 or 1;
nis 0, 1 or 2;
as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts.
The products are antibacterially active.
通式如下的头孢菌素衍生物
其中
R¹ 是源自羧酸的酰基;
杂环未被取代或被至少一个选自羧基、氨基、硝基、氰基、低级烷基、低级烷氧基、羟基、卤代烷基、卤代烯基、环烯基、低级炔基、芳烷基、芳氧基、芳烷氧基低级烷氧基、羟基、卤素、-CONR⁴R⁵、-N(R⁵)COOR⁹、R⁵CO-、R⁵OCO- 或 R⁵COO- 其中 R⁴ 是氢、低级烷基或环烷基;R⁵ 是氢或低级烷基; R⁹ 是氢、低级烷基、低级烯基或羧酸保护基团;
Q 是-CO-或-SO₂-;
mis 0 或 1;
n为 0、1 或 2;
以及其易于水解的酯、所述化合物的药学上可接受的盐和式 I 化合物及其酯和盐的水合物。
这些产品具有抗菌活性。